The global market for aortic stent grafts is forecasted to attain USD 3,981.9 million by 2025, expanding at 7.6% CAGR to reach USD 8,293.7 million by 2035. In 2024, the revenue of this market was around USD 3,715.4 million.
Over the years, the market for aortic stent grafts is anticipated to grow consecutively from 2025 to 2035. Increasing instances of aortic aneurysms, growing acceptability of minimally invasive procedures, and constant innovation in stent graft technology are escalating factors behind the growth of the market. In addition, the increase in cases of elderly persons, who are more prone to a variety of vascular-related diseases, has proven to be another expectation for market growth.
The use of advanced diagnostic technology and high success rates associated with surgery translates to increased patient-to-treatments with due course in time. Improvements in stent graft technology, such as enhanced durability and flexibility, also contribute to enhanced patient outcomes. Emerging technologies, such as 3D printing which can customize designs toward implants, in addition to drug-eluting stents, are still enhancing treatment efficacy.
Such technologies are certainly expected to make treatments more effective and safer. Collection on the third part of the future by blood donation g saffron. Some are bound to face challenges to the growth of markets, though. Excessive costs with stent graft procedures and strict regulatory clearances are going to make adoption difficult. In addition, potential complications such as graft migration or endo-leaks remain sources of concern to both patients and clinicians.
Despite these issues, rising investments in R&D and the development of bioresorbable stents are creating new opportunities. As companies focus on innovation, the market is bound to expand, offering improved treatment options for aortic aneurysms across the world.
Key Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 3,981.9 million |
| Industry Value (2035F) | USD 8,293.7 million |
| CAGR (2025 to 2035) | 7.6% |
Repeat technical advancements in the stent graft technology are widely contributing to market growth for the aortic stent grafts. Companies are creating next-gen stent grafts with added flexibility, sustainability, and efficient sealing mechanisms in order to promote better patient care. These measures minimize complications involving endo-leaks and migration of the graft, making surgical procedures more proficient and reliable.
The technology of 3D printing has facilitated the creation of patient-specific stent grafts, allowing for personalized therapy and improved procedural success. The development of drug-eluting stents is also avoiding restenosis and optimizing long-term graft performance. Novel materials, such as bioresorbable polymers, are also being explored to create stents that gradually erode after performing their function, reducing long-term hazards.
As technology continues to improve stent graft performance and safety, the rate of adoption will grow. Advances are not just improving treatment efficacy but also creating a larger market by making minimal invasive procedures available and effective on a wider scale.
Explore FMI!
Book a free demo
North America will dominate the aortic stent graft market due to its advanced healthcare infrastructure, high prevalence of aortic disease, and favorable reimbursement policies enabling patients to support advanced treatments. The region also witnesses growing use of endovascular aneurysm repair (EVAR) procedures, which are less invasive than open surgery, reducing the recovery time and risks related to the procedure.
Market leaders are investing aggressively in clinical trials and regulatory clearances to introduce advanced stent graft technology featuring better flexibility, durability, and sealability.
Further, the expanding occurrence of both hypertension and obesity, both highly associated with augmented risks of an aortic aneurysm, is accelerating demand for productive treatment options. Cardiovascular research efforts and policy backing of using AI-powered imaging diagnostic techniques, furthered through government policies supporting research, also continue to stimulate disease detection as well as the development of therapy planning, pushing overall market size growth. Continuous advances in technologies coupled with enabling healthcare policies guarantee that North America will lead the market for aortic stent grafts.
Europe maintains leadership in the market for aortic stent grafts on account of technologiocal advancement, an expanding elderly population base, and investment in cardiovascular research by the government. Major players in the industry, including Germany, France, and the UK, are spearheading the growth in stent graft adoption due to high stakes in clinical research trials and new product development that leads to further treatment improvement.
Strict regulatory policies in Europe guarantee the quality and safety of products, raising the confidence level of consumers in stent technology advancements. The growing knowledge among patients and physicians about minimally invasive interventions is also boosting the market growth. As increasing numbers of hospitals and specialty clinics incorporate endovascular aneurysm repair (EVAR) into their practice, next-generation stent graft demand will rise, thereby contributing to the overall market growth.
Asia Pacific aortic stent grafts market is estimated to see highest growth rate as a result of increasing investments in healthcare, increased access to novel treatments, and greater awareness regarding aortic disorders. China, Japan, and India are important contributors to the growth in the region with escalating demand for less invasive treatments and rising incidence of cardiovascular conditions.
The area is also being supported by the growth in medical tourism, which is pulling patients looking for affordable yet high-quality treatment possibilities. Governments are also actively applying policies to build cardiovascular care facilities, facilitating early diagnosis and improved treatment results. Furthermore, increasing presence of multinational healthcare companies is also driving faster adoption of newer stent graft technologies, resulting in additional expansion prospects in the region.
Challenges
High Costs of Stent Grafts and Regulatory Barriers Limiting the Market Growth
The expense of stent grafts is a major problem in the aortic stent grafts market, making it inaccessible, particularly in developing countries with limited healthcare budgets. Stent graft interventions, including endovascular aneurysm repair (EVAR), need costly medical devices, sophisticated imaging equipment, and specialized surgical skills, resulting in high total treatment costs.
Furthermore, cost burden is increased even more in some nations through restricted reimbursement schemes, thus subjecting patients to hardship in purchasing such life-sustaining operations. Smaller health facilities would also be hampered by resource constraints in being able to procure more sophisticated stent graft technology. Consequently, although minimally invasive aortic repairs have its advantages, elevated costs are an essential impediment to broader market uptake and expansion.
Opportunities
Advancements in Materials Science, Including Bioresorbable Stents Present Lucrative Growth Prospects
Materials science developments, especially the creation of bioresorbable stents, are generating high-value growth prospects for the market for aortic stent grafts. Bioresorbable stents are engineered to break down over time after contributing structural integrity, minimizing long-term issues like graft migration or restenosis.
Development of polymeric and nanomaterial-based stents is enhancing versatility, strength, and biocompatibility, making patient outcomes better. These new-generation stents also reduce the incidence of secondary interventions, which is a desirable factor for both patients and physicians. With further development in biodegradable materials, firms investing in bioresorbable stent technologies are bound to have an upper hand in the emerging market.
The market for aortic stent grafts showed a significant rise between 2020 and 2024 owing to the upsurge in aortic aneurysm cases, onset of minimally invasive endovascular aneurysm repair (EVAR) procedures, and the aging population. The demand for stent grafts has mainly been because they appear to be much safer, allowing for a quicker recovery of patients with a better outcome. However, device relocation with endoleaks and high procedural prices posed serious challenges to this market.
The period between 2025 and 2035 will see the completion of next-generation stents, including bioresorbable and drug-eluting grafts; AI is integrated with surgical planning and post-market stricter regulations to monitor long-term performance of the devices. The aptitude of 3D printers for developing stent grafts that exactly suit a particular condition in a patient skyrocket the procedural accuracy since such sustainability-conscious projects will also embrace biocompatible and eco-friendly materials.
| Category | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | FDA and CE approvals focused on safety and efficacy of stent grafts. Growing emphasis on post-market surveillance and device longevity. |
| Technological Advancements | EVAR and thoracic endovascular aneurysm repair (TEVAR) techniques improved outcomes. Limited use of patient-specific grafts. |
| Consumer Demand | High demand for minimally invasive procedures due to aging populations and rising aortic aneurysm cases. |
| Market Growth Drivers | Epidemiological growth of aortic aneurysm, improved imaging technology, and awareness about EVAR interventions. |
| Efforts towards sustainability | Improving the biocompatibility of materials while minimizing procedural waste. |
| Supply Chain Dynamics | Dependence on large USA and European manufacturers. Production cost and supply chain linkage during the COVID-19 crisis |
| Category | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Stricter long-term performance monitoring and safety regulations. Expansion of AI-assisted compliance tracking for stent graft durability. |
| Technological Advancements | Development of bioresorbable, drug-eluting, and AI-assisted stent grafts. 3D printing enables fully customized, patient-specific devices. |
| Consumer Demand | Increased demand for personalized and precision-medicine-based aortic repair solutions. Greater focus on long-term durability and reduced complications. |
| Market Growth Drivers | Growth of surgical planning through artificial intelligence, robot-assisted procedures, and advanced biomaterials enhancing the durability of the graft. |
| Efforts towards sustainability | Use of biodegradable and environmentally friendly stent material.Green manufacturing processes minimize the carbon footprint involved in device production |
| Supply Chain Dynamics | Diversification of manufacturing hubs. Localized production and 3D-printed grafts enhance supply chain resilience and cost efficiency. |
The USA aortic stent graft market is witnessing considerable growth owing to the prevalence of high incidences of aortic aneurysms and strong preference for minimal invasiveness. Increasing use of complex endovascular aneurysm repair techniques has also been instrumental in boosting market growth. Presence of renowned medical device players and high healthcare spending also attribute to the robust development of the market.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 6.1% |
The established healthcare infrastructure along with a preventive approach towards cardiovascular disease in this country would further expand the market for aortic stent grafts in the country. Moreover, early detection and treatment of aortic aneurysms are strongly focused upon by this country, which would encourage the use of stent graft technologies.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Germany | 6.2% |
Indian market is growing at a high pace, driven by expansion of enhanced healthcare infrastructure and rising awareness regarding cardiovascular disease. Increased occurrence of aortic aneurysms combined with the need for minimal interventions propels the market forward.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| India | 9.8% |
Japan's market for aortic stent grafts operates in a high-tech field of healthcare technology, which has seen a dent in the acceptance for minimally invasive therapies. The country also experiences a substantial burden due to the prevalence of aortic aneurysms and the aging population, thereby leading to the demand for effective therapies.
Market Growth Drivers
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 10.4% |
Due to the balanced stage of the health care system and the rising awareness of cardiovascular health, the Brazilian aortic stent graft market is growing. Another factors contributing to market growth is rising prevalence of aortic aneurysms as well as growing demand for minimally invasive procedures.
Market Growth Drivers
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Brazil | 5.1% |
Abdominal Aortic Stent Grafts Predominate the Market Due to The Prevalence of Abdominal Aortic Aneurysms (AAA), Particularly Among the Ageing Population
Abdominal aortic stent grafts dominate the market due to a prevalent abdominal aortic aneurysm (AAA), particularly in the older population. The stent grafts are used in endovascular aneurysm repair (EVAR), a less painful procedure than open surgery, with much reduced recovery time and operative complications. Increasing incidence of risk factors like hypertension, smoking, and aortic stent is fueling demand.
Technological advances, such as fenestrated and branched stent grafts, are enhancing outcomes by tailoring for anatomically complex patients. The fastest adoption is in North America and Europe by established healthcare systems and understanding of aortic disease. Growth in the Asia-Pacific region has occurred with greater access to endovascular intervention and greater investment in healthcare. Reimbursement and cost pressures remain the primary limitations to global adoption in some markets.
Advancements in Thoracic Aortic Stent Graft Materials Driving Growth in the Aortic Stent Grafts Market
Thoracic aortic stent grafts have a significant function in the management of TAA and dissections with mortality if left untreated. Stent grafts are employed in thoracic endovascular aortic repair, a less invasive treatment compared to the traditional open chest procedure. Increased incidence of aortic diseases and technological advancements in imaging and stent grafts are driving the market growth.
Next-generation devices such as low-profile delivery systems and hybrid stent grafts in complicated aortic arch disease are expanding treatment boundaries. This region is led by North America due to the presence of high aortic arch disease incidence and extensive use of TEVAR.
Followed by North America, there is Europe which is driven by strong regulatory and reimbursement forces. Developing economies in Latin America and Asia-Pacific are also expected to witness increased demand as healthcare centers get more advanced and more information on aortic aneurysm treatment is developed
The Availability of Advanced Imaging Technologies Driving Hospital Segment Growth
Hospitals represent the largest end-user segment for aortic stent grafts, as most EVAR and TEVAR procedures are performed in specialized vascular surgery units. The availability of advanced imaging technologies, hybrid operating rooms, and multidisciplinary surgical teams makes hospitals the preferred setting for aortic interventions.
The increasing prevalence of aortic aneurysms, coupled with rising adoption of minimally invasive procedures, is driving demand for stent grafts in hospital settings. Additionally, the growing number of high-risk patients requiring emergency aneurysm repairs further supports market expansion.
North America and Europe lead this segment due to well-established hospital networks and advanced surgical expertise. The Asia-Pacific region is witnessing increased demand as governments invest in tertiary care facilities and endovascular therapy training programs. However, the high cost of EVAR and TEVAR procedures continues to limit access in lower-income regions.
Increasing Shift Toward Outpatient Has Increased Demand for ASC/Outpatient Surgery Centers
With the increase in outpatient endovascular procedures performed, ambulatory surgical centers (ASCs) are emerging as an increasingly growing segment in the aortic stent graft market. Advances made in stent graft technology and efficiency of procedures have allowed some EVAR cases to be performed in ASCs to further reduce hospital stay durations and overall healthcare costs.
Same-day discharge convenience and a lower risk for hospital-acquired infections are already factors converting ASC users. Additionally, outpatient reimbursement policies tend to promote the push of procedures out of hospitals and into ASCs-particularly in North America and Europe.
However, because of the complexity of some aneurysm cases and the need for specialized imaging and surgical backup, TEVAR procedures have not yet found broad use in ASCs. As the minimally invasive techniques further evolve, the prospect of prescription in aortic aneurysm treatment is expected to favor ASCs, particularly in advanced healthcare markets.
The global aortic stent graft market is very competitive, with the presence of key global players and regional manufacturers stimulating innovation and growth in this market activity. The number of cases of aortic aneurysms is on the increase, with advances in minimally invasive surgical techniques and a large part of the world's population now considered elderly leading to technological advancements in aortic stent graft solutions.
Companies invest heavily in developing novel materials, enhanced durability, and precision-engineered designs to keep up with the competition; it is also the well-established players or emerging ones that characterize the market.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Medtronic | 33.5% |
| Cardinal Health, | 22.3% |
| Cook Medical Inc. | 15.3% |
| Becton, Dickinson and Company | 14.0% |
| CryoLife, Inc. (Artivion Inc.) | 5.1% |
| Other Companies (combined) | 9.8% |
| Company Name | Key Offerings/Activities (2024) |
|---|---|
| W. L. Gore & Associates Inc. | Has a wide range of aortic stent grafts focused on innovative designs and materials aimed at optimized patient outcomes |
| Medtronic Plc | Provides advanced endovascular stent graft systems used to treat aortic aneurysms and promotes minimally invasive treatment. |
| Cook Group Inc. | Excels at creating tailored stent graft solutions specific to each patient's anatomy, increasing procedural success rates. |
| Endologix LLC | The company is dedicated to the creation of new endovascular stent grafts intended to enhance durability and long-term performance |
| Terumo Corporation | Terumo Corporation supplies a range of aortic stent graft products, focusing on accuracy and reliability in endovascular procedures |
Key Company Insights
Medtronic Plc (33.5%)
Medtronic Plc, which is a technical leader in their field and offers access to innovative endovascular stent graft systems that enable minimally invasive surgery and are ideal to support the treatment of aortic aneurysm with better recovery times and fewer complications.
Cardinal Health (22.3%)
Cardinal Health is known to make a mark in the cardiovascular care industry through its array of medical devices and healthcare solutions used to treat aortic and vascular diseases. The company is crucial in providing stent graft technology and other key medical products to healthcare professionals. Cardinal Health is also concerned with digital health solutions and patient compliance programs, driving treatment success and better patient outcomes.
Cook Medical (15.3%)
Cook medical is a global medical devices company involved in designing personalized stent graft solutions specifically for individual patient anatomies to enhance procedural success rates and patient satisfaction.
Becton, Dickinson and Company (14.0%)
BD is one of the leaders in aortic stent grafts manufacturers that support minimally invasive cardiovascular intervening using a diverse range of medical devices and vascular access solutions. BD focuses on developing next-generation stent graft delivery systems and driving advancements in endovascular repair technology to help enhance patient care
CryoLife, Inc. (Artivion Inc.) (5.1%)
CryoLife, Inc. operates in the aortic stent grafts segment, focusing on with cardiovascular and aortic repair products. The company has gained popularity for its synthetic and biological graft technologies, such as stent grafts for aneurysms and dissections of the aorta. The company deals with developing novel implantable devices that improve surgical performance and increase survival rates for patients.
Beyond the leading companies, several other manufacturers contribute significantly to the market, enhancing product diversity and technological advancements. These include:
These companies focus on expanding the reach of advanced endovascular treatments, offering competitive pricing and cutting-edge aortic stent graft solutions.
The global aortic stent grafts industry is projected to witness CAGR of 7.6% between 2025 and 2035.
The global aortic stent grafts market stood at USD 3,715.4 million in 2024.
The global aortic stent grafts market is anticipated to reach USD 8,293.7 million by 2035 end.
India is expected to show a CAGR of 9.8% in the assessment period.
The key players operating in the global aortic stent grafts industry are Medtronic, Cardinal Health, Cook Medical Inc., Becton, Dickinson and Company, CryoLife, Inc. (Artivion Inc.), ENDOLOGIX, INC., Terumo Corporation Inc., Lombard Medical, Inc., W.L. Gore & Associates Inc., MicroPort Scientific Corporation and Others
Abdominal Aortic Stent Graft and Thoracic Aortic Stent Graft
Hospitals and ASC/Outpatient Surgery Centers
North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East & Africa
The Graft Versus Host Disease (GvHD) Treatment Market is segmented by Monoclonal antibodies, mTOR inhibitors, Tyrosine kinase inhibitors and Thalidomide from 2025 to 2035
The Breast Cancer Drug Market is segmented by Drug Class, and Distribution Channel from 2025 to 2035
Antibody-mediated Rejection Prevention Market Overview - Growth & Forecast 2025 to 2035
Anorectal Malformation Treatment Market - Trends & Therapeutic Innovations 2025 to 2035
Automated & Closed Cell Therapy Processing Systems Market Insights – Forecast 2025 to 2035
Antibody Therapy Market Insights - Growth, Demand & Forecast 2025 to 2035
Aortic Stent Grafts Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
